Mydecine Innovations Valuation

MYCOF Stock  USD 0.01  0.00  0.00%   
Mydecine Innovations seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Mydecine Innovations from analyzing the firm fundamentals such as Shares Owned By Insiders of 8.71 %, return on equity of -12.24, and Current Valuation of 8.64 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
0.01
Please note that Mydecine Innovations' price fluctuation is out of control at this time. Calculation of the real value of Mydecine Innovations is based on 3 months time horizon. Increasing Mydecine Innovations' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Mydecine pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Mydecine Innovations Group. Since Mydecine Innovations is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mydecine Pink Sheet. However, Mydecine Innovations' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.005 Real  0.0041 Hype  0.005593 Naive  0.005538
The real value of Mydecine Pink Sheet, also known as its intrinsic value, is the underlying worth of Mydecine Innovations Company, which is reflected in its stock price. It is based on Mydecine Innovations' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Mydecine Innovations' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
0
Real Value
41.92
Upside
Estimating the potential upside or downside of Mydecine Innovations Group helps investors to forecast how Mydecine pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mydecine Innovations more accurately as focusing exclusively on Mydecine Innovations' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
00.010.01
Details
Hype
Prediction
LowEstimatedHigh
0.000.0141.93
Details
Naive
Forecast
LowNext ValueHigh
0.00010.0141.92
Details

Mydecine Innovations Total Value Analysis

Mydecine Innovations Group is now estimated to have takeover price of 8.64 M with market capitalization of 5.94 M, debt of 4.35 M, and cash on hands of 324.15 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Mydecine Innovations fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
8.64 M
5.94 M
4.35 M
324.15 K

Mydecine Innovations Investor Information

The company recorded a loss per share of 4.68. Mydecine Innovations last dividend was issued on the 1st of April 2019. The entity had 1:45 split on the 1st of April 2019. Based on the key indicators related to Mydecine Innovations' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Mydecine Innovations Group is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.

Mydecine Innovations Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mydecine Innovations has an asset utilization ratio of 0.0988 percent. This implies that the Company is making $9.88E-4 for each dollar of assets. An increasing asset utilization means that Mydecine Innovations Group is more efficient with each dollar of assets it utilizes for everyday operations.

Mydecine Innovations Ownership Allocation

Mydecine Innovations Group secures 8.71 % of its outstanding shares held by insiders and 0.0 % owned by institutional investors.

Mydecine Innovations Profitability Analysis

The company reported the revenue of 7.49 K. Net Loss for the year was (28.9 M) with profit before overhead, payroll, taxes, and interest of 7.49 K.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Mydecine Innovations' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Mydecine Innovations and how it compares across the competition.

About Mydecine Innovations Valuation

The pink sheet valuation mechanism determines Mydecine Innovations' current worth on a weekly basis. Our valuation model uses a comparative analysis of Mydecine Innovations. We calculate exposure to Mydecine Innovations's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mydecine Innovations's related companies.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Mydecine Innovations operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11 people.

8 Steps to conduct Mydecine Innovations' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Mydecine Innovations' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Mydecine Innovations' valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Mydecine Innovations' financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Mydecine Innovations' revenue streams: Identify Mydecine Innovations' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Mydecine Innovations' industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Mydecine Innovations' growth potential: Evaluate Mydecine Innovations' management, business model, and growth potential.
  • Determine Mydecine Innovations' financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Mydecine Innovations' estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Mydecine Innovations Growth Indicators

Investing in growth stocks can be very risky. If the company such as Mydecine Innovations does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding5.2 M
Retained Earnings-124.9 M

Complementary Tools for Mydecine Pink Sheet analysis

When running Mydecine Innovations' price analysis, check to measure Mydecine Innovations' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mydecine Innovations is operating at the current time. Most of Mydecine Innovations' value examination focuses on studying past and present price action to predict the probability of Mydecine Innovations' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mydecine Innovations' price. Additionally, you may evaluate how the addition of Mydecine Innovations to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets